NCT03036930 2026-03-11
Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
23 trialsNCT01932697 2026-02-10
Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
Mayo Clinic
Phase 2 Completed
NCT01898494 2025-02-28
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT03487549 2024-11-27
COVE-1
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT03981822 2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT02258659 2024-09-24
OPTIMA
University of Chicago
Phase 2 Completed
NCT01084083 2023-06-28
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT03258008 2022-12-16
Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01693783 2022-11-08
Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03937791 2021-04-13
Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02482428 2021-01-05
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
Novartis
Phase 2 Completed
NCT01209325 2020-08-11
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
AIDS Malignancy Consortium
Phase 2 Completed
NCT00586339 2020-01-03
Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females
GlaxoSmithKline
Phase 2 Completed
NCT00359619 2020-01-02
Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine
GlaxoSmithKline
Phase 2 Completed
NCT00231413 2019-12-12
Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.
GlaxoSmithKline
Phase 2 Completed
NCT02706691 2019-04-16
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
University of Chicago
Phase 2 Terminated
NCT00309166 2018-09-17
Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.
GlaxoSmithKline
Phase 2 Completed
NCT00546078 2018-06-26
Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America
GlaxoSmithKline
Phase 2 Completed
NCT01585428 2018-03-07
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00411749 2017-04-21
V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00378560 2017-04-17
V501 Efficacy Study in Women Aged 18 to 26 (V501-027)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00518336 2016-12-09
Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil
GlaxoSmithKline
Phase 2 Completed
NCT00303823 2015-05-05
Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia
National Cancer Institute (NCI)
Phase 2 Completed